| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal HST33: Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over |
|
Medicine details |
|
| Medicine name | leniolisib (Joenja®) |
| Formulation | oral formulation |
| Reference number | 5081 |
| Indication | Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 years and older |
| Company | Pharming Group NV |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/03/2023 |
| NICE guidance | |